Biobanking is a rapidly growing industry that is expected to revolutionize healthcare. With increasing investments in regenerative medicine and personalized medicine, biobanks are becoming crucial for drug discovery and understanding the genetic basis of human diseases.

The demand for medical data sets in biobanks has led to the rise of precision medicine, which aims to provide personalized treatments and develop new drugs. Biomarkers, which are indicators of diseases, are also being identified to aid in early detection, treatment, and prevention of conditions like neurological disorders, cardiovascular disease, and cancer.

The global biobanking industry size was valued at USD 66.66 billion in 2021, and it is projected to grow at a CAGR of 4.6% between 2022 and 2030. Despite the disruptions caused by the COVID-19 pandemic, biobanks and researchers collaborated to develop vaccines and therapies. Virtual biobanks, which store biosamples from multiple clinical sites, played a significant role in these efforts.

Cell banks are expected to experience significant growth in the coming years due to advancements in cryopreservation and stem cell therapy. The California Institute for Regenerative Medicine recently invested USD 89 million into stem cell and gene therapy research, indicating the growing interest and potential in this field.

Induced pluripotent stem cell (iPSC) therapy is gaining momentum as it eliminates the need for donor matching and immunosuppressant usage. This technology allows for the development of personalized beta cell replacement therapy, as demonstrated by the collaboration between Sernova and Evotec.

The global cell banking outsourcing market was valued at USD 9.86 billion in 2021 and is expected to grow at a CAGR of approximately 16.39% through 2030.

Several mega-trends and opportunities are shaping the future of the biobanking industry:

1. Soaring cancer cases are driving the demand for DNA and RNA banking services, which play a crucial role in understanding the molecular basis of cancer and developing targeted therapies.
2. Cord blood banking services, which involve storing umbilical cord blood for potential future use, have gained popularity due to the increased interest in personalized banking and cold blood transplants.
3. North America is emerging as a favorable investment hub, with significant funds being allocated to drug discovery and biobank development to ensure safety and reliability.

In Europe, the biobanking industry has seen significant growth due to the emphasis on personalized treatment and investments in research activities. Several EU member states have signed the 1+ Million Genomes Initiative, which aims to collect and analyze genomic data to improve healthcare outcomes. In the UK, BioGrad recently opened the country’s second-largest biobank facility in Liverpool, offering parents the opportunity to preserve their stem cells.

The competitive landscape in the biobanking industry is diverse, with both established and emerging players making investments in research and development, product offerings, geographical expansion, mergers and acquisitions, and partnerships. For example, Merck & Co. recently acquired Prometheus Biosciences for approximately USD 10.8 billion to enhance its immunology drug pipeline.

Overall, the biobanking industry is poised for significant growth and innovation in the coming years, driven by advancements in technology, increased collaborations, and the rising demand for personalized medicine.